Harrow, Inc. (HROW) · Oct 5, 2026 · Acquisition
$30M acquisition — $30M cash at closing; up to $70M in sales-based milestones
Harrow closes its TYRVAYA acquisition, adding a second branded dry-eye therapy and targeting more than $30 million in 2027 revenue.
Harrow is moving from a single-product dry-eye growth story around VEVYE toward a broader branded ocular-surface franchise. VEVYE was already showing strong prescription and coverage momentum, while management had framed TYRVAYA as the next portfolio addition and expected the transaction to close in the second half of 2026.
The transaction is now completed, but the core news was already known. Harrow paid $30.0 million in cash and could owe up to another $70.0 million if TYRVAYA reaches specified sales thresholds through 2029. The acquisition had been announced in August, so the closing confirms execution rather than creating a fresh strategic surprise. 〔0〕
| Item | Filing detail |
|---|---|
| Upfront cash consideration | $30.0 million (Purchase Agreement) |
| Potential contingent milestones | Up to $70.0 million (Purchase Agreement) |
| Maximum stated consideration | Up to $100.0 million (Financial details) |
| Expected TYRVAYA revenue in 2027 | More than $30 million (Press release) |
| Additional personnel expected to join | Approximately 40 (Commercial integration) |
The deal strengthens Harrow’s dry-eye commercial platform more than it changes the near-term financial picture. TYRVAYA gives Harrow a differentiated nasal treatment alongside VEVYE, while the incoming Viatris personnel and shared specialty-pharmacy infrastructure are intended to increase prescriber coverage and reduce duplication across the portfolio. The company says TYRVAYA will be available immediately, with integration beginning in the fourth quarter of 2026. 〔1〕
The Japan carveout makes the closing economics cleaner, not larger. Viatris keeps Japanese commercialization rights, while Harrow receives tiered royalties there and the parties may later negotiate a collaboration. In exchange, the post-closing working-capital adjustment was removed and the cash payment was fixed at $30.0 million.
The main test shifts from deal completion to commercial execution. Management is targeting more than $30 million of TYRVAYA revenue in 2027, a target already disclosed when the acquisition was announced, so this filing does not raise the business outlook by itself. It does, however, remove closing risk and put the combined sales force, distribution setup, and cross-selling thesis into operation.
Bottom line: This is a strategically meaningful portfolio expansion, but today’s filing mostly confirms an anticipated transaction rather than changing expectations. The value now depends on whether Harrow can convert TYRVAYA’s existing prescriber base and larger sales team into the stated 2027 revenue contribution without disrupting VEVYE’s momentum.
TYRVAYA commercial integration and 2027 revenue delivery
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.